Entera Bio Ltd. Cost of Revenue

Cost of Revenue of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending June 29, 2020 was $31 Thousand (a -26.19% decrease compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue decreased by -22.5%
  • Annual Cost of Revenue for 2019 was $210 Thousand
  • Twelve month Cost of Revenue ending June 29, 2020 was $221 Thousand (a -12.3% decrease compared to previous quarter)
Trailing Cost of Revenue for the last four month:
29 Jun '20 30 Mar '20
$221 Thousand $252 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Entera Bio Ltd.

Most recent Cost of Revenueof ENTX including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Entera Bio Ltd.

Entera Bio Ltd. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.03 $0.04
2019 $0.11 $0.04 $0.06 $0.21

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.